Tetraphase Pharmaceuticals Inc. (TTPH) Receives $7.14 Consensus Target Price from Analysts

Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) has received a consensus recommendation of “Hold” from the twelve ratings firms that are currently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and six have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $7.14.

Several brokerages have commented on TTPH. SunTrust Banks reiterated a “buy” rating and set a $10.00 target price on shares of Tetraphase Pharmaceuticals in a research report on Wednesday, February 14th. Stifel Nicolaus dropped their target price on shares of Tetraphase Pharmaceuticals from $13.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, February 14th. HC Wainwright dropped their target price on shares of Tetraphase Pharmaceuticals from $17.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, February 14th. B. Riley began coverage on shares of Tetraphase Pharmaceuticals in a research report on Monday, February 12th. They set a “buy” rating and a $11.00 target price for the company. Finally, Gabelli upgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, March 29th.

How to Become a New Pot Stock Millionaire

In other Tetraphase Pharmaceuticals news, insider Jacques Dumas sold 7,167 shares of the company’s stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $6.21, for a total transaction of $44,507.07. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 5.50% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. SG Americas Securities LLC bought a new stake in shares of Tetraphase Pharmaceuticals in the 3rd quarter valued at $107,000. Cubist Systematic Strategies LLC bought a new stake in shares of Tetraphase Pharmaceuticals in the 3rd quarter valued at $195,000. Paloma Partners Management Co bought a new stake in shares of Tetraphase Pharmaceuticals in the 4th quarter valued at $210,000. American International Group Inc. increased its position in shares of Tetraphase Pharmaceuticals by 44.1% in the 3rd quarter. American International Group Inc. now owns 33,826 shares of the biopharmaceutical company’s stock valued at $231,000 after buying an additional 10,345 shares in the last quarter. Finally, Virtus Fund Advisers LLC bought a new stake in shares of Tetraphase Pharmaceuticals in the 4th quarter valued at $376,000. Institutional investors and hedge funds own 58.50% of the company’s stock.

NASDAQ:TTPH traded down $0.07 during trading hours on Tuesday, hitting $3.08. 376,450 shares of the stock were exchanged, compared to its average volume of 1,294,694. Tetraphase Pharmaceuticals has a twelve month low of $2.05 and a twelve month high of $8.76. The company has a market cap of $158.91, a price-to-earnings ratio of -1.17 and a beta of 2.61.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its quarterly earnings data on Thursday, March 8th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.64) by $0.18. Tetraphase Pharmaceuticals had a negative return on equity of 90.75% and a negative net margin of 1,187.17%. The firm had revenue of $2.53 million for the quarter, compared to the consensus estimate of $2.26 million. analysts forecast that Tetraphase Pharmaceuticals will post -1.58 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Tetraphase Pharmaceuticals Inc. (TTPH) Receives $7.14 Consensus Target Price from Analysts” was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3341581/tetraphase-pharmaceuticals-inc-ttph-receives-7-14-consensus-target-price-from-analysts.html.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

New Age Beverages  Stock Price Down 9.4% on Analyst Downgrade
New Age Beverages Stock Price Down 9.4% on Analyst Downgrade
Scotiabank Reiterates C$4.75 Price Target for Premier Gold Mines
Scotiabank Reiterates C$4.75 Price Target for Premier Gold Mines
BMO Capital Markets Increases Roots  Price Target to C$16.00
BMO Capital Markets Increases Roots Price Target to C$16.00
Syntel  Trading -0.6% Higher  After Strong Earnings
Syntel Trading -0.6% Higher After Strong Earnings
BNP Paribas Reiterates CHF 74 Price Target for Nestle
BNP Paribas Reiterates CHF 74 Price Target for Nestle
Roche  Given a CHF 230 Price Target at Morgan Stanley
Roche Given a CHF 230 Price Target at Morgan Stanley


Leave a Reply

© 2006-2018 Ticker Report. Google+.